A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
Open Access
- 20 June 2019
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 121 (2) , 131-138
Abstract
Background Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in non-small-cell lung cancer (NSCLC). TSR-011 is a dual ALK and tropomyosin-related kinase (TRK) inhibitor, active against ALK inhibitor resistant tumours in preclinical studies. Here, we report the safety, tolerability and recommended phase 2 dose (RP2D) of TSR-011 in patients with relapsed or refractory ALK- and TRK-positive advanced cancers. Methods In this sequential, open-label, phase 1 trial (NCT02048488), patients received doses of 30 mg, escalated to 480 mg every 24 hours (Q24h), followed by an expansion cohort of patients with ALK-positive cancers. The primary objective was to evaluate safety and tolerability. Secondary objectives included pharmacokinetics. Results TSR-011 320- and 480-mg Q24h doses exceeded the maximum tolerated dose. At the RP2D of 40 mg every 8 hours (Q8h), the most common grade 3–4 treatment-emergent adverse events occurred in 3.2–6.5% of patients. Of 14 ALK inhibitor-naive patients with ALK-positive NSCLC, 6 experienced partial responses and 8 had stable disease. Conclusions At the RP2D (40 mg Q8h), TSR-011 demonstrated a favourable safety profile with acceptable QTc changes. Limited clinical activity was observed. Based on the competitive ALK inhibitor landscape and benefit/risk considerations, further TSR-011 development was discontinued. Clinical trial registration number NCT02048488.Keywords
Funding Information
- This clinical trial was funded by TESARO, Inc.
This publication has 15 references indexed in Scilit:
- ALK: a tyrosine kinase target for cancer therapyCold Spring Harbor Molecular Case Studies, 2017
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung CancerCancer Discovery, 2016
- Crizotinib resistance: implications for therapeutic strategiesAnnals of Oncology, 2016
- NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesESMO Open, 2016
- ALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsTherapeutic Advances in Medical Oncology, 2015
- 19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility LocusCancer Research, 2012
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- The biology and treatment of EML4-ALK non-small cell lung cancerEuropean Journal of Cancer, 2010
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences, 2008
- Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cellsOncogene, 2004